• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Affimed N.V. (Amendment)

    2/14/23 2:12:34 PM ET
    $AFMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AFMD alert in real time by email
    SC 13G/A 1 affimed13ga1-123122.htm AMENDMENT NO. 1 TO THE SCHEDULE 13G
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C.  20549
    SCHEDULE 13G
    (RULE 13d - 102)
    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b)
    (Amendment No. 1)*
    Affimed N.V.
    (Name of Issuer)
    Common Shares, nominal value €0.01 per share
    (Title of Class of Securities)
    N01045108
    (CUSIP Number)
    December 31, 2022
    (Date of Event which Requires Filing of this Statement)
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [ ]            Rule 13d-1(b)
    [x]            Rule 13d-1(c)
    [ ]            Rule 13d-1(d)
    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


    1.
    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
       
     
    683 Capital Management, LLC
       
    2.
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
     
    (a)    [ ]
     
    (b)    [ ]
       
    3.
    SEC USE ONLY
       
    4.
    CITIZENSHIP OR PLACE OF ORGANIZATION
       
     
    Delaware
       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:
       
    5.
    SOLE VOTING POWER
       
     
    0
       
    6.
    SHARED VOTING POWER
       
     
    9,106,250*
       
    7.
    SOLE DISPOSITIVE POWER
       
     
    0
       
    8.
    SHARED DISPOSITIVE POWER
       
     
    9,106,250*
       
    9.
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
     
    9,106,250*
       
    10.
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
    EXCLUDES CERTAIN SHARES    [ ]
       
    11.
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
     
    6.2%
       
    12.
    TYPE OF REPORTING PERSON
       
     
    IA
     
    * Including warrants to purchase 106,250 Common Shares.



    1.
    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
       
     
    683 Capital Partners, LP
       
    2.
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
     
    (a)    [ ]
     
    (b)    [ ]
       
    3.
    SEC USE ONLY
       
    4.
    CITIZENSHIP OR PLACE OF ORGANIZATION
       
     
    Delaware
       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:
       
    5.
    SOLE VOTING POWER
       
     
    0
       
    6.
    SHARED VOTING POWER
       
     
    9,106,250*
       
    7.
    SOLE DISPOSITIVE POWER
       
     
    0
       
    8.
    SHARED DISPOSITIVE POWER
       
     
    9,106,250*
       
    9.
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
     
    9,106,250*
       
    10.
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
    EXCLUDES CERTAIN SHARES    [ ]
       
    11.
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
     
    6.2%
       
    12.
    TYPE OF REPORTING PERSON
       
     
    PN
     
    * Including warrants to purchase 106,250 Common Shares.


    1.
    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
       
     
    Ari Zweiman
       
    2.
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
     
    (a)    [ ]
     
    (b)    [ ]
       
    3.
    SEC USE ONLY
       
    4.
    CITIZENSHIP OR PLACE OF ORGANIZATION
       
     
    United States of America
       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:
       
    5.
    SOLE VOTING POWER
       
     
    0
       
    6.
    SHARED VOTING POWER
       
     
    9,106,250*
       
    7.
    SOLE DISPOSITIVE POWER
       
     
    0
       
    8.
    SHARED DISPOSITIVE POWER
       
     
    9,106,250*
       
    9.
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
     
    9,106,250*
       
    10.
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
    EXCLUDES CERTAIN SHARES    [ ]
       
    11.
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
     
    6.2%
       
    12.
    TYPE OF REPORTING PERSON
       
     
    IN
     
    * Including warrants to purchase 106,250 Common Shares.


    Item 1(a).
    Name of Issuer:
    Affimed N.V. (“Issuer”)
    Item 1(b).
    Address of Issuer’s Principal Executive Offices:
    Im Neuenheimer Feld 582, 69120 Heidelberg, Germany.
    Item 2(a).
    Name of Persons Filing:
    The names of the persons filing this statement on Schedule 13G (collectively, the “Reporting Persons”) are:

    •
    683 Capital Management, LLC,


    •
    683 Capital Partners, LP, and


    •
    Ari Zweiman.

    Item 2(b).
    Address of Principal Business Office or, if None, Residence:
    The principal business address for each of the Reporting Persons is 1700 Broadway, Suite 4200, New York, NY 10019.
    Item 2(c).
    Citizenship:
    683 Capital Management, LLC is a Delaware limited liability company. 683 Capital Partners, LP is a Delaware limited partnership. Ari Zweiman is a citizen of the United States.
    Item 2(d).
    Title of Class of Securities:
    Common Shares, nominal value €0.01 per share (the “Common Shares”)
    Item 2(e).
    CUSIP Number:
    N01045108
    Item 3.
    If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
     
    (a)
    [ ]
    Broker or dealer registered under Section 15 of the Exchange Act.
           
     
    (b)
    [ ]
    Bank as defined in Section 3(a)(6) of the Exchange Act.
           
     
    (c)
    [ ]
    Insurance company defined in Section 3(a)(19) of the Exchange Act.
           
     
    (d)
    [ ]
    Investment company registered under Section 8 of the Investment Company Act.
           
     
    (e)
    [ ]
    Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
           
     
    (f)
    [ ]
    Employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
           
     
    (g)
    [ ]
    Parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
           
     
    (h)
    [ ]
    Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
           


     
    (i)
    [ ]
    Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
           
     
    (j)
    [ ]
    Non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J).
           
     
    (k)
    [ ]
    Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

    Item 4.
    Ownership.
    (a)
    Amount beneficially owned:
    As of December 31, 2022, 683 Capital Partners, LP beneficially owned 9,106,250 Common Shares, which includes 106,250 Common Shares issuable upon the exercise of outstanding warrants.
    683 Capital Management, LLC, as the investment manager of 683 Capital Partners, LP, may be deemed to have beneficially owned the 9,106,250 Common Shares beneficially owned by 683 Capital Partners, LP.
    Ari Zweiman, as the Managing Member of 683 Capital Management, LLC, may be deemed to have beneficially owned the 9,106,250 Common Shares beneficially owned by 683 Capital Management, LLC.
    (b)
    Percent of Class:
    The following percentage is based on 145,919,772 Common Shares outstanding as of April 14, 2022, as disclosed in the Issuer’s 424B5 (Prospectus) filed on April 14, 2022, plus 106,250 shares issuable upon the exercise of outstanding warrants that are freely exercisable within 60 days.
    As of December 31, 2022, the Reporting Persons may be deemed to have beneficially owned approximately 6.2% of the outstanding Common Shares.
    (c)
    Number of shares as to which such person has:

    (i)
    Sole power to vote or to direct the vote of Common Shares:
    See Cover Pages Items 5-9.

    (ii)
    Shared power to vote or to direct the vote of Common Shares:
    See Cover Pages Items 5-9.

    (iii)
    Sole power to dispose or to direct the disposition of Common Shares:
    See Cover Pages Items 5-9.

    (iv)
    Shared power to dispose or to direct the disposition of Common Shares:
    See Cover Pages Items 5-9.
    Item 5.
    Ownership of Five Percent or Less of a Class.
    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following [   ].


    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.
    Not applicable.
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
    Not applicable.
    Item 8.
    Identification and Classification of Members of the Group.
    See Exhibit A to Schedule 13G filed on February 7, 2022.
    Item 9.
    Notice of Dissolution of Group.
    Not applicable.
    Item 10.
    Certification.
    By signing below the undersigned certifies that, to the best of its or his knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    SIGNATURES
    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.
    Dated:  February 14, 2023
    683 CAPITAL MANAGEMENT, LLC*
     
       
    By:
    /s/ Ari Zweiman
     
     
    Ari Zweiman,
     
     
    Managing Member
     

    683 CAPITAL PARTNERS, LP*
     
       
    By:
    /s/ Ari Zweiman
     
     
    Ari Zweiman,
     
     
    Authorized Person
     

    /s/ Ari Zweiman
     
    ARI ZWEIMAN*
     

    *The Reporting Persons disclaim beneficial ownership in the Common Shares reported herein except to the extent of their pecuniary interest therein.
    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative.  If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference.  The name and any title of each person who signs the statement shall be typed or printed beneath his signature.
    Note.  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.
    Attention.  Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001)

    Get the next $AFMD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AFMD

    DatePrice TargetRatingAnalyst
    5/14/2025Buy → Neutral
    H.C. Wainwright
    5/13/2025Outperform → Market Perform
    Leerink Partners
    12/12/2022$6.00Buy
    H.C. Wainwright
    10/10/2022$9.00 → $2.00Buy → Hold
    Stifel
    8/18/2022Overweight
    Wells Fargo
    3/31/2022$7.00Overweight
    Piper Sandler
    2/23/2022$12.00Overweight
    Cantor Fitzgerald
    10/21/2021$10.00Buy
    Truist
    More analyst ratings

    $AFMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Affimed Announces Receipt of Nasdaq Delisting Notice

      MANNHEIM, Germany, May 14, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received a written notice from the staff of the Nasdaq Listing Qualifications Department (the "Staff") notifying the Company that, in accordance with Nasdaq Listing Rule 5101, 5110(b) and IM-5101-1, the trading of the Company's common shares will be suspended at the opening of business on May 20, 2025, and a Form 25 Notification of Delisting will be filed with the U.S. Securities Exchange Commission to delist the Company's securities from The Nasdaq Stock Market ("Nasdaq")

      5/14/25 6:45:00 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Affimed Announces Filing for the Opening of Insolvency Proceedings

      MANNHEIM, Germany, May 13, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced its decision to file an application for opening of insolvency proceedings with the local court of Mannheim in Germany. As previously reported, Affimed N.V. (the "Company") has been engaged in discussions with potential investors and partners with respect to potential strategic transactions to raise additional capital. Despite its continuous and ongoing fundraising efforts, the Company has not been able to raise sufficient additional funds to continue the operations of the Company and

      5/13/25 8:15:00 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting

      An exposure-outcome analysis in 72 patients with refractory non-small cell lung cancer (NSCLC) who received AFM24 at 480 mg weekly demonstrates that higher drug exposure (above median) leads to improved objective response rate (33.3% vs 5.6%) and longer progression free survival (PFS) (7.3 mo. vs 2.9 mo.) without a negative impact on safetyThese findings will be incorporated in future AFM24 trials to further improve efficacy outcomes of patients treated with AFM24 MANNHEIM, Germany, April 29, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today presented findings on an ex

      4/29/25 10:00:00 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AFMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Affimed Therapeutics downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Affimed Therapeutics from Buy to Neutral

      5/14/25 8:54:15 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Affimed Therapeutics downgraded by Leerink Partners

      Leerink Partners downgraded Affimed Therapeutics from Outperform to Market Perform

      5/13/25 8:52:30 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Affimed Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Affimed Therapeutics with a rating of Buy and set a new price target of $6.00

      12/12/22 7:32:36 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AFMD
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Affimed N.V.

      SCHEDULE 13G/A - Affimed N.V. (0001608390) (Subject)

      5/20/25 4:01:22 PM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Affimed N.V.

      6-K - Affimed N.V. (0001608390) (Filer)

      5/14/25 7:16:40 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Affimed N.V.

      6-K - Affimed N.V. (0001608390) (Filer)

      5/13/25 8:22:43 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AFMD
    Financials

    Live finance-specific insights

    See more
    • Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer

      MANNHEIM, Germany, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD) ("Affimed", or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will host a conference call on Tuesday, December 17, at 8:30 a.m. EST / 14:30 CET to review clinical data from AFM24-102, the combination trial of its AFM24 innate cell engager ICE® with atezolizumab in non-small cell lung cancer. The conference call will be available via phone and webcast. The live audio webcast of the call will be available in the "Webcasts" section on the "Investors" page of the Affimed website at https://www.affimed.com/in

      12/9/24 6:30:00 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Affimed Reports Third Quarter 2024 Financial Results & Business Update

      AFM24 combination with atezolizumab: The non-small cell lung cancer (NSCLC) EGFR wild-type (EGFRwt) cohort completed enrollment: Objective response rate (ORR) and safety data to be presented on a Company conference call on December 17, 2024.Acimtamig (AFM13) combination with AlloNK® (AB-101): Updated clinical data from the four cohorts of the run-in phase to be presented in a poster session at ASH 2024.AFM28 monotherapy phase 1 dose-escalation study: Updated clinical data to be presented at an oral presentation at ASH 2024.Cash runway into Q4 2025: As of September 30, 2024, cash, cash equivalents and investments were €24.1 million. Based on operating and financial plans cash-runway projected

      11/14/24 6:30:00 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024

      MANNHEIM, Germany, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release third quarter 2024 results and corporate update on Thursday, November 14, 2024. The Company will host a conference call at 8:30 a.m. EST / 14:30 CET. The conference call will be available via phone and webcast. The live audio webcast of the call will be available in the "Webcasts" section on the "Investors" page of the Affimed website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/. To access the call by phone, please use link https://r

      11/6/24 6:30:00 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AFMD
    Leadership Updates

    Live Leadership Updates

    See more
    • Affimed Appoints Shawn M. Leland as Chief Executive Officer

      MANNHEIM, Germany, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD) ("Affimed" or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that Shawn M. Leland, PharmD, RPh has been appointed as Chief Executive Officer (CEO). Dr. Andreas Harstrick, who has been serving as acting CEO since January 2024 will continue in his position as Chief Medical Officer (CMO). Shawn is an accomplished pharmaceutical and biotechnology professional with more than 15 years of experience in the industry. He has a proven track record in successfully advancing the development of novel oncology assets, rais

      9/3/24 7:45:00 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Affimed Announces Addition of Dr. Constanze Ulmer-Eilfort to its Supervisory Board

      HEIDELBERG, Germany, June 22, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD) ("Affimed", or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the appointment of Dr. Constanze Ulmer-Eilfort to its Supervisory Board. Dr. Ulmer-Eilfort's appointment was approved during the Annual General Meeting of Shareholders which took place on June 21, 2023. "We are delighted to announce the appointment of Dr. Ulmer-Eilfort to our Supervisory Board," said Dr. Thomas Hecht, Chairman of Affimed's Supervisory Board. "Constanze brings a wealth of legal expertise and a deep understanding of the biotech and he

      6/22/23 6:30:00 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Affimed Announces Appointment of Uta Kemmerich-Keil to its Supervisory Board

      HEIDELBERG, Germany, June 16, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the appointment of Ms. Uta Kemmerich-Keil as director on its Supervisory Board effective immediately. The appointment was approved during the Annual General Meeting of Shareholders on June 15, 2021. "We are pleased to welcome Uta to Affimed's Supervisory Board," said Dr. Thomas Hecht, Chairman of the Supervisory Board. "Uta brings unique and very deep and extensive executive experience in the life sciences industry. With over 20 years of leadership roles in driving higher busine

      6/16/21 7:04:39 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AFMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Affimed N.V.

      SC 13G - Affimed N.V. (0001608390) (Subject)

      10/24/24 2:49:52 PM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Affimed N.V. (Amendment)

      SC 13G/A - Affimed N.V. (0001608390) (Subject)

      2/14/24 4:07:21 PM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Affimed N.V. (Amendment)

      SC 13G/A - Affimed N.V. (0001608390) (Subject)

      2/13/24 1:20:05 PM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care